Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LILRA6 CAR-T in Relapsed/Refractory Acute Myeloid Leukemia
NCT07263906Phase 1Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Dec 2025
- Primary completion
- Oct 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of anti-LILRA6 CAR-T cells in acute myeloid leukemia (AML), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Dose Limiting Toxicity at 28 days. Started Dec 2025; status: recruiting.
02
Drugs
anti-LILRA6 CAR-T cells
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07263906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07263906.